Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Mar 1, 2016
SOLANA BEACH, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today provided an update on enrollment of its ongoing Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide...
Mar 1, 2016
SOLANA BEACH, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today provided an update on enrollment of its ongoing Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of...
Feb 17, 2016
SOLANA BEACH, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's successful thorough electrocardiogram (ECG) study of EVK-001, its metoclopramide nasal spray product candidate, w...
Feb 17, 2016
SOLANA BEACH, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's successful thorough electrocardiogram (ECG) study of EVK-001, its metoclopramide nasal spray product candidate, were acc...
Nov 12, 2015
SOLANA BEACH, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2015. Dave Gonyer, R.Ph., President and CEO, stated, "This was an exciting quar...
Nov 10, 2015
SOLANA BEACH, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be participating in the Brean Capital 2015 Life Sciences Summit on Monday, November 16, 2015 at the Mil...
Nov 5, 2015
SOLANA BEACH, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of the market. Evoke will hol...
Oct 7, 2015
SOLANA BEACH, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the amendment of its loan and security agreement with Square 1 Bank (the "credit facility") to extend the interest-only payment term for an additional 1...
Sep 28, 2015
SOLANA BEACH, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company has reached a key milestone under its $4.5 million loan and security agreement (the credit facility) with Square 1 Bank (Square 1). A...
Sep 15, 2015
SOLANA BEACH, Calif., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its Phase 3 clinical trial design for EVK-001 (metoclopramide nasal spray) is consistent with the FDA's recommendations in the recently released ...
Aug 18, 2015
SOLANA BEACH, Calif., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's concurrence with the Company's proposed pediatric stud...
Aug 13, 2015
Enrolled 130 total subjects in Phase 3 clinical trial through end of July Recent FDA draft guidance of advice on Gastroparesis mirrors Evoke's Phase 3 clinical trial protocol design SOLANA BEACH, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for ...
Jul 30, 2015
SOLANA BEACH, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2015 on Thursday, August 13, 2015, after the close of the market. Evoke will...
Jul 1, 2015
SOLANA BEACH, Calif., July 1, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Wednesday, July 8, 2015 at 10:15 AM ET at the Cantor Fitzgerald Inaugural Healthcare Conference. The conference is being held on J...
Jun 24, 2015
SOLANA BEACH, Calif., June 24, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that previously disclosed results from its Phase 2b clinical trial evaluating EVK-001, its patented intranasal delivery formulation of metoclopramide f...
= add release to Briefcase